CIK 1958125
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 71.47% | 27 |
| Unclassified | 12.67% | 6 |
| Health Care Equipment & Supplies | 9.31% | 6 |
| Life Sciences Tools & Services | 3.58% | 1 |
| Health Care Providers & Services | 2.96% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Health Care | 9.82% |
| 2 | BBIO | BridgeBio Pharma, Inc. | Health Care | 6.70% |
| 3 | ASND | Ascendis Pharma A/S | Health Care | 6.17% |
| 4 | BMY | BRISTOL MYERS SQUIBB CO | Health Care | 5.33% |
| 5 | SNDX | Syndax Pharmaceuticals Inc | Health Care | 5.09% |
| 6 | GILD | GILEAD SCIENCES, INC. | Health Care | 4.77% |
| 7 | TERNS PHARMACEUTICALS INC | Unclassified | 4.50% | |
| 8 | DFTX | Definium Therapeutics, Inc. | Health Care | 4.10% |
| 9 | SOLENO THERAPEUTICS INC | Unclassified | 4.04% | |
| 10 | BSX | BOSTON SCIENTIFIC CORP | Health Care | 3.92% |
35/41 names classified · sector 87.3% of weight · industry 87.3% · mkt cap 80.1%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 87.3% of the book is sector-classified (unclassified names shown, never dropped).
Only 20% of book weight classified — the grid is NOT representative of the whole book.
Classified: 20.0% of book weight (5/39 names) · unclassified 80.0%: , DNTH, BBIO, ASND, SNDX, DFTX, RARE, CYTK, NTRA, CRVS +24 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | DNTHDIANTHUS THERAPEUTICS INC | 560,308 | $47M | 9.8% | TRIM −14% |
| 2 | BBIOBRIDGEBIO PHARMA INC | 432,014 | $32M | 6.7% | NEW |
| 3 | ASNDASCENDIS PHARMA A/S | 129,111 | $30M | 6.2% | ADD 8% |
| 4 | BMYBRISTOL-MYERS SQUIBB CO | 420,727 | $26M | 5.3% | TRIM −35% |
| 5 | SNDXSYNDAX PHARMACEUTICALS INC | 1,043,670 | $24M | 5.1% | TRIM −13% |
| 6 | GILDGILEAD SCIENCES INC | 163,905 | $23M | 4.8% | TRIM −43% |
| 7 | TERNS PHARMACEUTICALS INC | 409,031 | $22M | 4.5% | ADD 199% |
| 8 | DFTXDEFINIUM THERAPEUTICS INC COM SHS | 1,037,984 | $20M | 4.1% | NEW |
| 9 | SOLENO THERAPEUTICS INC | 577,808 | $19M | 4.0% | ADD 60% |
| 10 | BSXBOSTON SCIENTIFIC CORP | 299,318 | $19M | 3.9% | TRIM −17% |
| 11 | RAREULTRAGENYX PHARMACEUTICAL IN | 850,797 | $18M | 3.7% | ADD 423% |
| 12 | INCYINCYTE CORP | 182,101 | $17M | 3.6% | NEW |
| 13 | CYTKCYTOKINETICS INC | 215,501 | $14M | 3.0% | TRIM −17% |
| 14 | NTRANATERA INC | 70,907 | $14M | 3.0% | ADD 14% |
| 15 | CRVSCORVUS PHARMACEUTICALS INC | 891,933 | $13M | 2.7% | NEW |
| 16 | GPCRSTRUCTURE THERAPEUTICS INC | 255,379 | $12M | 2.6% | HOLD |
| 17 | MLYSMINERALYS THERAPEUTICS INC | 439,041 | $12M | 2.5% | ADD 32% |
| 18 | EWEDWARDS LIFESCIENCES CORP | 144,607 | $12M | 2.4% | TRIM −23% |
| 19 | MANEVeradermics Inc | 173,582 | $11M | 2.3% | NEW |
| 20 | ADPTADAPTIVE BIOTECHNOLOGIES COR | 722,784 | $10M | 2.1% | TRIM −12% |
| 21 | HTFLHEARTFLOW INC | 403,588 | $10M | 2.1% | ADD 254% |
| 22 | KALVISTA PHARMACEUTICALS INC | 426,551 | $9M | 1.8% | NEW |
| 23 | QUREUNIQURE NV | 491,116 | $8M | 1.7% | ADD 70% |
| 24 | IRONDISC MEDICINE INC | 122,978 | $8M | 1.6% | ADD 11% |
| 25 | SEPNSEPTERNA INC | 294,360 | $7M | 1.5% | HOLD |
| 26 | ABVXABIVAX SA | 47,193 | $5M | 1.1% | TRIM −52% |
| 27 | DYNDYNE THERAPEUTICS INC | 282,954 | $5M | 1.1% | TRIM −46% |
| 28 | ELDNELEDON PHARMACEUTICALS INC | 1,639,816 | $5M | 1.1% | ADD 30% |
| 29 | KPTIKARYOPHARM THERAPEUTICS INC | 897,709 | $5M | 1.0% | ADD 528% |
| 30 | SUPNSUPERNUS PHARMACEUTICALS INC | 62,019 | $3M | 0.7% | TRIM −76% |
| 31 | TARAPROTARA THERAPEUTICS INC | 580,024 | $3M | 0.6% | TRIM −60% |
| 32 | PHATPHATHOM PHARMACEUTICALS INC | 247,767 | $3M | 0.6% | TRIM −65% |
| 33 | NAMSNEWAMSTERDAM PHARMA COMPANY | 83,554 | $3M | 0.6% | NEW |
| 34 | TYRATYRA BIOSCIENCES INC | 67,285 | $3M | 0.5% | NEW |
| 35 | IMCRIMMUNOCORE HLDGS PLC | 84,352 | $3M | 0.5% | NEW |
| 36 | GUTSFRACTYL HEALTH INC | 5,491,866 | $3M | 0.5% | HOLD |
| 37 | HYPRHYPERFINE INC | 1,320,041 | $1M | 0.3% | HOLD |
| 38 | MGXMETAGENOMI INC | 528,993 | $708,851 | 0.1% | HOLD |
| 39 | ATAIATAIBECKLEY INC | 196,858 | $696,877 | 0.1% | NEW |
| 40 | FTHSENSEI BIOTHERAPEUTICS INC | 14,718 | $463,911 | 0.1% | HOLD |
| 41 | OMOUTSET MED INC | 118,279 | $454,191 | 0.1% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| DNTHDIANTHUS THERAPEUTICS INC | 763K | 763K | 747K | 668K | 654K | 560K | $47M |
| BBIOBRIDGEBIO PHARMA INC | 898K | 963K | 928K | 623K | — | 432K | $32M |
| ASNDASCENDIS PHARMA A/S | 216K | 196K | 180K | 145K | 119K | 129K | $30M |
| BMYBRISTOL-MYERS SQUIBB CO | 499K | — | — | — | 648K | 421K | $26M |
| SNDXSYNDAX PHARMACEUTICALS INC | — | 1.7M | 2.1M | 1.6M | 1.2M | 1.0M | $24M |
| GILDGILEAD SCIENCES INC | — | — | 227K | — | 289K | 164K | $23M |
| TERNS PHARMACEUTICALS INC | — | — | — | — | 137K | 409K | $22M |
| DFTXDEFINIUM THERAPEUTICS INC COM SHS | — | — | — | — | — | 1.0M | $20M |
| SOLENO THERAPEUTICS INC | — | 161K | 410K | 418K | 360K | 578K | $19M |
| BSXBOSTON SCIENTIFIC CORP | 73K | — | 229K | 263K | 360K | 299K | $19M |
| RAREULTRAGENYX PHARMACEUTICAL IN | — | — | 213K | 291K | 163K | 851K | $18M |
| INCYINCYTE CORP | — | — | — | — | — | 182K | $17M |
| CYTKCYTOKINETICS INC | 458K | 586K | 601K | 452K | 258K | 216K | $14M |
| NTRANATERA INC | — | — | 97K | 148K | 62K | 71K | $14M |
| CRVSCORVUS PHARMACEUTICALS INC | — | — | — | — | — | 892K | $13M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
